⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INSM News
Insmed, Inc.
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
globenewswire.com
SNGX
PFE
MRK
BMY
INSM
Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery
prnewswire.com
XOM
MSFT
GOOG
AMZN
NVDA
TSLA
META
BABA
JD
PDD
NTES
BILI
ZNH
RRBT
HSAI
UBOT
WRDE
HSTR
INST
UNIS
GEL
TIGR
ZLAB
CNBC
SRCH
APM
SMY
AMDX
SCNL
ASPB
YXT
INSM
MLTX
LNV
STEF
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
prnewswire.com
INSM
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
prnewswire.com
INSM
Insmed To Present at November and December 2025 Investor Conferences
prnewswire.com
INSM
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
prnewswire.com
INSM
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
prnewswire.com
INSM
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
prnewswire.com
INSM
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
prnewswire.com
INSM
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
prnewswire.com
INSM